随机抽提100例无血缘关系的广东汉族人的血痕DNA,用PCR法扩增载脂蛋白B(apolipoprotein B apoB)基因3′端的VNTR,共检出19个等位基因,片段大小分布在510～1200bp之间,等位基因频率为0.005—0.195,杂合度为88.80％,父权排除率为0.6395,...随机抽提100例无血缘关系的广东汉族人的血痕DNA,用PCR法扩增载脂蛋白B(apolipoprotein B apoB)基因3′端的VNTR,共检出19个等位基因,片段大小分布在510～1200bp之间,等位基因频率为0.005—0.195,杂合度为88.80％,父权排除率为0.6395,其等位基因数目及频率分布均与英国白种人的有差异。家系分析表明扩增片段按孟德尔方式遗传。本实验证实了apoB基因3′端VNTR的高度多态性和高度杂合性。展开更多
Endostatin, a 20 kD (184 aa) C-teminal fragment of collagenⅩⅧ,is the most potent inhibitor of tumor angiogenesis described so for. Endostatin was initially isolated from a murine hemangioendothelioma cell line (EOMA...Endostatin, a 20 kD (184 aa) C-teminal fragment of collagenⅩⅧ,is the most potent inhibitor of tumor angiogenesis described so for. Endostatin was initially isolated from a murine hemangioendothelioma cell line (EOMA). Purified recombinant murine endostatin generated in E.coli bacteria injected as unfolded suspension, inhibited the growth of a varity of metastatic and primary tumors in mice. However, its widespread application has been hampered by difficulties in the large-scale production of the antiangiogenic proteins. The limitation may be resolved by in vivo delivery and expression of the antitangiogenic gene. This review summarized the advances in endostain research in recent years including structure, the mechanism of generating ,function and therapy.展开更多
文摘随机抽提100例无血缘关系的广东汉族人的血痕DNA,用PCR法扩增载脂蛋白B(apolipoprotein B apoB)基因3′端的VNTR,共检出19个等位基因,片段大小分布在510～1200bp之间,等位基因频率为0.005—0.195,杂合度为88.80％,父权排除率为0.6395,其等位基因数目及频率分布均与英国白种人的有差异。家系分析表明扩增片段按孟德尔方式遗传。本实验证实了apoB基因3′端VNTR的高度多态性和高度杂合性。
文摘Endostatin, a 20 kD (184 aa) C-teminal fragment of collagenⅩⅧ,is the most potent inhibitor of tumor angiogenesis described so for. Endostatin was initially isolated from a murine hemangioendothelioma cell line (EOMA). Purified recombinant murine endostatin generated in E.coli bacteria injected as unfolded suspension, inhibited the growth of a varity of metastatic and primary tumors in mice. However, its widespread application has been hampered by difficulties in the large-scale production of the antiangiogenic proteins. The limitation may be resolved by in vivo delivery and expression of the antitangiogenic gene. This review summarized the advances in endostain research in recent years including structure, the mechanism of generating ,function and therapy.
